3 Great Reasons Why GlaxoSmithKline plc Is Set To Take Off

Royston Wild looks at the major share price drivers for GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at why I believe GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is the right tonic for investors seeking bumper returns from their invested cash.

Bubbly pipeline yielding exciting growth opps

Like many giants across the pharma space, GlaxoSmithKline has suffered heavily for several years now from the patent expiration for many of its key drugs. But the company has been vigilant in developing its pipeline to offset this and drive future earnings growth.

Indeed, the firm has received US approval for its Breo Ellipta, Tafinlar and Mekinist drugs in recent months, and is expected to receive Phase III testing data for around a dozen or so more potential earnings drivers during 2013.

And GlaxoSmithKline’s latest budding earnings generator received US Food and Drug Administration (FDA) approval just last month. Tivicay — developed by its ViiV Healthcare joint venture — is an integrase inhibitor used to block the spread of the HIV virus, and is used alongside other antiretroviral agents for the treatment of HIV-1. A Reuters study showed sales of the drug could reach $900m by 2017.

An active M&A player

To complement the heavy investment it has ploughed into R&D, GlaxoSmithKline remains a shrewd operator on the acquisition front and last month affirmed its commitment to conclude value-accretive bolt-on purchases through its substantial cash pile.

Recent purchases include Swiss vaccine development specialist Okairos in May for £214m, a move that will give the company access to cutting-edge technology to boost its vaccine offerings. And GlaxoSmithKline is not afraid to embark on mammoth game-changing deals, its $3bn purchase of Human Genome Sciences last August giving it total control of the Benlysta lupus treatment.

A dependable dividend deliverer

This pharmaceutical play is a smart selection for those seeking chubby, and increasingly-generous, dividend income. GlaxoSmithKline has steadily increased the full-year payout in recent years, even during times of severe earnings pressure, and total payouts have risen 30% over the past five years, hitting 74p per share in 2012.

And City analysts expect last year’s dividend to increase to 77.4p and 82p per share in 2013 and 2014 respectively, via healthy rises of 5% and 6%. And these prospective payments currently carry yields of 4.6% and 4.9% respectively.

These yields compare extremely favourable with an average forward payment of 2.4% for the pharmaceuticals and biotechnology sector, and 3.2% for the FTSE 100.

The right tonic for stunning shareholder returns

I reckon that GlaxoSmithKline is the right prescription for  savvy investors seeking strong earnings potential. And if you are looking for a whole host of other FTSE 100 winners to bolster your investment returns, I strongly recommend you check out these recommendations from veteran fund manager Neil Woodford.

Woodford — in charge of UK Equities at Invesco Perpetual — has more than 30 years’ experience in the industry, and has marked out two other fantastic pharmaceutical giants ready to generate monumental gains.

This exclusive report, compiled by The Motley Fool’s crack team of analysts, is totally free and comes with no further obligation. Click here now to download your copy.

> Royston does not own shares in GlaxoSmithKline. The Motley Fool has recommended GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

ISA Individual Savings Account
Investing Articles

Thinking of starting a Stocks and Shares ISA this April? Avoid these 4 mistakes!

A Stocks and Shares ISA can be a way for an investor to try and build wealth over the long…

Read more »

ISA coins
Investing Articles

Here’s how to build a £100k ISA starting with £5k today

Increase an ISA's value 20-fold? It need not just be the stuff of dreams, according to this writer -- though…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

6.9% yield! I just added this share to my SIPP

In a turbulent stock market, our writer has been hunting for bargains to add to his SIPP. After a 31%…

Read more »

piggy bank, searching with binoculars
Investing Articles

With Rolls-Royce shares moving up again, is a £10 price target back on the horizon?

Rolls-Royce shares wobbled when President Trump dropped his tariff bombshell on us. But three weeks is a short time in…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

2 UK stocks to consider buying as the market sell-off continues

Stephen Wright thinks investors looking for opportunities might be able to take advantage of short-term weakness in some UK stocks.

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

1 stock for passive income investors to consider buying before the Bank of England cuts interest rates

With the Bank of England’s Monetary Policy Committee set to meet in May, passive income investors should think about how…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

Is Tesla about to become the ultimate passive income machine?

Our writer discusses whether Tesla stock might be worth him buying, just in case the EV giant enables passive income…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Will the Rolls-Royce share price collapse? Here’s what the charts say

The Rolls-Royce share price has pulled back following the announcement of Donald Trump’s trade policy, but supportive trends remain.

Read more »